Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs

Bioorg Med Chem Lett. 2002 Feb 11;12(3):341-4. doi: 10.1016/s0960-894x(01)00731-4.

Abstract

A series of compounds (22-36) which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxSIs, such as Ridogrel (1).

MeSH terms

  • Animals
  • Drug Design
  • Enzyme Inhibitors / chemistry*
  • Humans
  • In Vitro Techniques
  • Indicators and Reagents
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / chemistry*
  • Platelet Membrane Glycoproteins / antagonists & inhibitors*
  • Platelet Membrane Glycoproteins / chemistry
  • Rabbits
  • Receptors, Cell Surface*
  • Receptors, G-Protein-Coupled*
  • Structure-Activity Relationship
  • Thromboxane-A Synthase / antagonists & inhibitors*
  • Thromboxane-A Synthase / chemistry

Substances

  • Enzyme Inhibitors
  • Indicators and Reagents
  • Platelet Aggregation Inhibitors
  • Platelet Membrane Glycoproteins
  • Receptors, Cell Surface
  • Receptors, G-Protein-Coupled
  • platelet activating factor receptor
  • Thromboxane-A Synthase